Literature DB >> 7847874

Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium.

F G Hayden1, B S Rollins, L K Madren.   

Abstract

The anti-influenza activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en (4-G-NAc) was determined in Madin-Darby canine kidney (MDCK) cells by yield reduction and ELISA and in explants of human respiratory epithelium by yield reduction. In MDCK cells, 50% inhibitory concentrations (EC50) averaged 0.5 microgram/ml for influenza A/Virginia/88(H3N2) and 0.04 microgram/ml for A/Texas/36/91(H1N1) by ELISA, and < 0.01 microgram/ml for influenza A/Virginia by yield reduction. In human adenoid explants, concentrations causing at least 1.0 log10 TCID50/ml decrease in yield (EC90) at 48 h were < 0.01 microgram/ml for A(H1N1) and A(H3N2) viruses and 0.25 microgram/ml for B/Hong Kong/5/72. 100 micrograms/ml 4-G-NAc did not inhibit outgrowth of human adenoid epithelium at 6 days, whereas ribavirin 10 micrograms/ml reduced outgrowth by > 50%. 4-G-NAc is a potent and selective inhibitor of clinical isolates of influenza A and B viruses in human respiratory epithelium.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7847874     DOI: 10.1016/0166-3542(94)90101-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  13 in total

Review 1.  Zanamivir.

Authors:  S L Waghorn; K L Goa
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Blood group antigens: molecules seeking a function?

Authors:  P Greenwell
Journal:  Glycoconj J       Date:  1997-02       Impact factor: 2.916

Review 3.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

4.  Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.

Authors:  D P Calfee; A W Peng; L M Cass; M Lobo; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 5.  Zanamivir: an update of its use in influenza.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Zanamivir: a review of its use in influenza.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

7.  Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.

Authors:  D B Mendel; C Y Tai; P A Escarpe; W Li; R W Sidwell; J H Huffman; C Sweet; K J Jakeman; J Merson; S A Lacy; W Lew; M A Williams; L Zhang; M S Chen; N Bischofberger; C U Kim
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group.

Authors:  F Y Aoki; D M Fleming; A D Griffin; L A Lacey; S Edmundson
Journal:  Pharmacoeconomics       Date:  2000-02       Impact factor: 4.981

9.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 10.  New approaches to influenza chemotherapy. Neuraminidase inhibitors.

Authors:  D P Calfee; F G Hayden
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.